Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
St. Justine's Hospital
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cellectar Biosciences, Inc.
Children's Oncology Group
Dana-Farber Cancer Institute
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cancer Research UK
St. Jude Children's Research Hospital
University of Wisconsin, Madison
National Cancer Institute (NCI)
Children's Oncology Group
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Pfizer
Hoffmann-La Roche
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
University of Virginia
University Hospital, Basel, Switzerland
Children's Oncology Group
Bayer
National Cancer Institute (NCI)
City of Hope Medical Center
AbbVie
Bristol-Myers Squibb
West China Hospital
Roswell Park Cancer Institute
National Institutes of Health Clinical Center (CC)
Jonsson Comprehensive Cancer Center
Children's Oncology Group
Novartis
Children's Oncology Group
Acrotech Biopharma Inc.
National Institutes of Health Clinical Center (CC)
Vanderbilt-Ingram Cancer Center
National Institutes of Health Clinical Center (CC)
City of Hope Medical Center